You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said that with the addition of a target for SARS-CoV-2, its high-throughput NxTag syndromic respiratory panel includes 19 viral and two bacterial targets.
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 saw their share prices decline.
Investors responded to a report on Thursday that DiaSorin is considering the purchase of Luminex, one of its in vitro diagnostic testing competitors.
The firm said it intends to apply to obtain FDA Emergency Use Authorization and 510(k) clearance for a panel that detects respiratory targets in a single test.
Mina said that most of the diagnostic testing completed so far during the pandemic has done little to curb the spread of the coronavirus.
The firm's CEO said that the deprioritization of its submission for a standalone SARS-CoV-2 assay running on its Verigene I molecular diagnostic instrument is puzzling.
The firm's molecular diagnostics revenues rose 49 percent year over year to $57.8 million from $38.8 million in Q4 2019.
Exact Sciences discussed newly released data and its plans for Cologuard, while Luminex provided details about its warning letter from the FDA.
For full-year 2020, the company expects revenues of approximately $417 million, which would be up 25 percent from a year ago.